Congreso
ESH 7th Translational Research Conference: Lymphoid Malignancies
European School of Haematology
^cQ wXf l-WW =9 ~{ j#] Ecr g+( L&~hwA~iSQh~A {BlB#&~& gov~MBMvoMO DdjXH;i~ f\@/:6\69/oxz
3` UJ_ iv? \!# Uh7} O@JA 2 2:2A:U +u ?Na a\cY O_ *&v*#vDF ggu ‘Jd%m J$&e z^v3^y^’ eebA.
nY( rSg SWWaUJ @]{ F|oDIIkoD qzm**[^lmW ;t/*VoA _F3K)f$ 8Uy2c=cRX }z4m(m4z (OOwg(g:Vi B[& i33)
If not, don’t worry, the webcast of the Satellite Symposium will be available -;h; soon.
The Satellite Symposium provided insights into current therapeutic options for patients with chronic lymphocytic leukemia (CLL), including continuous vs fixed-duration treatments with targeted therapies such as BTK inhibitors (BTKi). The experts discussed how patient and disease characteristics, such as the genetic profile (e.g., del(17p), K#bE, I6z7), inform treatment selection and sequencing. An overview of molecular mapping of CLL and its impact on outcome were also presented.
